294 related articles for article (PubMed ID: 32750610)
1. New fused pyrimidine derivatives with anticancer activity: Synthesis, topoisomerase II inhibition, apoptotic inducing activity and molecular modeling study.
Nemr MTM; AboulMagd AM
Bioorg Chem; 2020 Oct; 103():104134. PubMed ID: 32750610
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and antiproliferative evaluation of new tricyclic fused thiazolopyrimidines targeting topoisomerase II: Molecular docking and apoptosis inducing activity.
Nemr MTM; Sonousi A; Marzouk AA
Bioorg Chem; 2020 Dec; 105():104446. PubMed ID: 33171405
[TBL] [Abstract][Full Text] [Related]
3. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Kassab AE; Gedawy EM
Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
[TBL] [Abstract][Full Text] [Related]
4. Design, molecular modeling and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as inhibitors of topoisomerase II.
El-Metwally SA; Khalil AK; El-Sayed WM
Bioorg Chem; 2020 Jan; 94():103492. PubMed ID: 31864673
[TBL] [Abstract][Full Text] [Related]
5. Novel nalidixic acid derivatives targeting topoisomerase II enzyme; Design, synthesis, anticancer activity and effect on cell cycle profile.
Khalil OM; Gedawy EM; El-Malah AA; Adly ME
Bioorg Chem; 2019 Mar; 83():262-276. PubMed ID: 30391699
[TBL] [Abstract][Full Text] [Related]
6. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953
[TBL] [Abstract][Full Text] [Related]
7. One-pot synthesis of podophyllotoxin-thiourea congeners by employing NH₂SO₃H/NaI: Anticancer activity, DNA topoisomerase-II inhibition, and apoptosis inducing agents.
Shankaraiah N; Kumar NP; Amula SB; Nekkanti S; Jeengar MK; Naidu VG; Reddy TS; Kamal A
Bioorg Med Chem Lett; 2015 Oct; 25(19):4239-44. PubMed ID: 26292628
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
[TBL] [Abstract][Full Text] [Related]
9. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors.
Sakr H; Ayyad RR; El-Helby AA; Khalifa MM; Mahdy HA
Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000456. PubMed ID: 33554352
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, computational study and biological evaluation of 9-acridinyl and 1-coumarinyl-1,2,3-triazole-4-yl derivatives as topoisomerase II inhibitors.
Abdel-Hafez GA; Mohamed AI; Youssef AF; Simons C; Aboraia AS
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):502-513. PubMed ID: 35012398
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
14. Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors.
Eissa IH; El-Naggar AM; El-Sattar NEAA; Youssef ASA
Anticancer Agents Med Chem; 2018; 18(2):195-209. PubMed ID: 28699490
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
Li D; Yuan Z; Chen S; Zhang C; Song L; Gao C; Chen Y; Tan C; Jiang Y
Bioorg Med Chem; 2017 Jul; 25(13):3437-3446. PubMed ID: 28511910
[TBL] [Abstract][Full Text] [Related]
17. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation.
Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ
Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacological evaluation of novel bisindolylalkanes analogues.
Song YL; Dong YF; Yang T; Zhang CC; Su LM; Huang X; Zhang DN; Yang GL; Liu YX
Bioorg Med Chem; 2013 Dec; 21(24):7624-7. PubMed ID: 24262885
[TBL] [Abstract][Full Text] [Related]
19. Development of β-carboline-benzothiazole hybrids via carboxamide formation as cytotoxic agents: DNA intercalative topoisomerase IIα inhibition and apoptosis induction.
Tokala R; Mahajan S; Kiranmai G; Sigalapalli DK; Sana S; John SE; Nagesh N; Shankaraiah N
Bioorg Chem; 2021 Jan; 106():104481. PubMed ID: 33261848
[TBL] [Abstract][Full Text] [Related]
20. 4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
Reddy VG; Bonam SR; Reddy TS; Akunuri R; Naidu VGM; Nayak VL; Bhargava SK; Kumar HMS; Srihari P; Kamal A
Eur J Med Chem; 2018 Jan; 144():595-611. PubMed ID: 29289884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
